



## Supplementary information




**Supplementary Fig. 1 Identification of interacting proteins with m<sup>1</sup>A modified probes. a**

The m<sup>1</sup>A and m<sup>6</sup>A contents of m<sup>1</sup>A probes from human 28S rRNA gene were quantified by LC-MS/MS. **b** PAGE gel resolution of immunoprecipitated m<sup>1</sup>A probes and its associated proteins from Raw264.7 and HEK293T by silver staining. Different bands were analyzed by MS. **c** PAGE gel resolution of immunoprecipitated YTHDF3 proteins from HEK293T by silver staining. Red \* indicates the YTHDF3 bands. **d-f** Overlap of control probes and m<sup>1</sup>A probes associated proteins in Raw264.7 (**d**), HEK293T (**e**), and overlap of common associated protein between Raw264.7 and HEK293T (**f**). **g** IP and immunoblot analyses of the indicated probes in trophoblast HTR8/SVneo transfected with YTHDF3 plasmid. Data are shown as representative photographs.



**Supplementary Fig. 2 Transcriptome analysis of trophoblast upon YTHDF3 knockdown.**


Graphs of the significantly changed genes in HTR-8/SVneo upon YTHDF3 knockdown.



### Supplementary Fig. 3 Gene Ontology (GO) and KEGG analysis of YTHDF3-binding


mRNAs. **a** Confocal microscopy of HTR-8/SVneo treated in hypoxia for 12 h or stimulated with LPS (100ng/mL) for 6 h as indicated, then stained with YTHDF3 antibodies. Scale bar, 10  $\mu$ m. **b** Gel electrophoresis analysis of cDNA treated as indicated for removing free RT primers and size selection. **c** Gel image of amplified cDNA libraries and extraction of the indicated size

ranges. **d,e** Overlap of two biological replicates for iCLIP in normoxia (**d**) or hypoxia (**e**) HTR-8/SVneo cells. **f** Overlap of transcripts identified by iCLIP of YTHDF3 in normoxia or hypoxia HTR-8/SVneo cells. Numbers in **d,e,f** show the sum of genes identified in each sample. **g,h** GO and KEGG analysis of the enriched YTHDF3-binding RNAs in normoxia cells but not in that of the hypoxia cells. **i,j** GO and KEGG analysis of the enriched YTHDF3-bound RNAs in hypoxia cell but not in that of normoxia cell. Red \* indicates the enriched signaling pathway changed upon hypoxia. Data are representative of three independent experiments with similar results (**a,b,c**).




**Supplementary Fig. 4 m<sup>1</sup>A map of trophoblast induced by hypoxia identified by m<sup>1</sup>A-seq.** **a** Histograms showing the changes in m<sup>1</sup>A enrichment in the hypoxia versus normoxia treated HTR-8/SVneo cells. **b** Metagene plots showing the average distribution of m<sup>1</sup>A peaks identified across all transcripts in HTR8/SVneo treated with or without hypoxia for 12 h. **c,d** GO and KEGG analysis of the transcripts with disappeared m<sup>1</sup>A modification in HTR-8/SVneo cells upon hypoxia. **e,f** GO and KEGG analysis of the transcripts with new occurred m<sup>1</sup>A modification in HTR-8/SVneo cells upon hypoxia. **g** Enrichment fold of the indicated RNA transcripts in m<sup>6</sup>A IP versus RNA input control. Red \* indicates the enriched signaling pathway upon hypoxia. NS: not significant; \*\*p<0.01 (Student's t-test). Data are representative of three independent experiments (mean and s.d. of

technical triplicates (**g**).



**Supplementary Fig. 5 ALKBH5 knockdown did not affect the expression of IGF1R.** **a** RNA lifetime for IGF1R in HTR-8/SVneo transfected with shControl or shALKBH3 was determined by monitoring transcript abundance after transcription inhibition (TI). **b** qRT-PCR and immunoblot analysis of IGF1R mRNA in HTR-8/SVneo transfected with shControl or shALKBH5 for 72 h. NS: not significant. \* $p < 0.05$  (Student's t-test). Data are representative of three independent experiments (mean and s.d. of technical triplicates (**a,b**)).



**Supplementary Fig. 6 IGF1R mRNA was efficiently knocked down by RNA interfering.**

**a** qRT-PCR analysis of the IGF1R mRNA in HTR8/SVneo transfected with IGF1R siRNA #1 or #2 as indicated for 48 h. **b** qRT-PCR analysis of the MMP2 mRNA in HTR8/SVneo transfected with IGF1R siRNA #1 for 48 h. **c** Immunoblot analysis of the IGF1R protein in HTR8/SVneo transfected with IGF1R plasmid for 48 h. **d** qRT-PCR analysis of the MMP2 mRNA in HTR8/SVneo transfected with IGF1R plasmid for 48 h. \*\* $p < 0.01$  (Student's t-test). Data are representative of three independent experiments (mean and s.d. of technical triplicates (**a**, **b**, **d**)).



**Supplementary Table S1 Overlap of proteins pulled down by m<sup>1</sup>A probe between Raw264.7 and HEK293T.**

Gene Name	Raw264.7			HEK293T		
	Score	Matches	emPAI	Score	Matches	emPAI
ATP synthase subunit alpha, mitochondrial (ATP5A1)	389	24(17)	0.8	41	4(2)	0.11
78 kDa glucose-regulated protein (HSPA5)	265	20(12)	0.56	32	4(2)	0.09
Transcriptional activator protein Pur-alpha (PURA)	132	7(6)	0.44	38	8(4)	0.44
Heterogeneous nuclear ribonucleoprotein M (HNRNPM)	116	8(4)	0.18	23	2(2)	0.09
ADP/ATP translocase 2 (SLC25A5)	90	14(4)	0.33	39	4(1)	0.1
RNA-binding protein 28 (RBM28)	65	6(2)	0.08	17	6(1)	0.04
Poly(rC)-binding protein 1 (PCBP1)	65	7(3)	0.18	152	6(5)	0.4
YTH domain-containing family protein 3 (YTHDF3)	35	5(3)	0.16	165	13(10)	0.49
RuvB-like 2 (RUVBL2)	34	3(2)	0.06	28	5(1)	0.06

**Supplementary Table S2 Flowchart of YTHDF3 iCLIP-seq alignment and processing pipeline, resulting in peaks and genes.**

	Normoxia		Hypoxia	
	Replicate 1	Replicate 2	Replicate 1	Replicate 2
Input	62,513,192	76,072,511	71,932,433	40,094,128
Mapped	47,366,424	56,910,397	55,228,446	28,010,060
Mapped/input	75.77%	74.81%	76.78%	69.86%
Peaks	889	1,076	589	567
Genes	168	240	156	170

**Supplementary Table S3 Flowchart of m<sup>1</sup>A-seq alignment and processing pipeline, resulting in peaks and genes.**

	Normoxia		Hypoxia	
	Replicate 1 IP	Replicate 2 IP	Replicate 1 IP	Replicate 2 IP
Input	50,822,999	42,879,965	68,974,324	70,008,453
Mapped	48,913,621	41,257,415	66,451,984	67,095,701
Mapped/input	96.24%	96.22%	96.34%	95.84%
Peaks		580		190
Genes		489		181

**Supplementary Table S4 siRNA sequences used for RNA interference**

Human Genes		siRNA sequences (5' to 3')
<i>IGF1R</i>	sense #1	GCGGAGAGAUGUCAUGCAATT
	antisense #1	UUGCAUGACAUCUCUCCGCTT
	sense #2	GCUUCACCGUUUACUACAATT
	antisense #2	UUGUAGUAAACGGUGAAGCTT
<i>Negative control</i>	sense	UUCUCCGAACGUGUCACGUTT
	antisense	ACGUGACACGUUCGGAGAATT

**Supplementary Table S5 Lentiviral shRNA sequences used for gene interference**

Human Genes		shRNA sequences (5' to 3')
<i>Ythdf3</i>	target seq #1	CCTATGGACAAATGAGTAA
	target seq #2	GCAGTGGTATGACTAGCAT
<i>Alkbh3</i>	target seq	GGAACAGCTTTGTCAAGAT
<i>Alkbh5</i>	target seq	TCGTGTCCGTGTCCTTCTT
<i>Trmt6</i>	target seq	CTGAAACGTGAAGATGTGT
<i>Negative control</i>	target seq	TTCTCCGAACGTGTCACGT

**Supplementary Table S6 Primers used for qRT-PCR**

Human Genes		Primer sequences (5' to 3')
<i>YTHDF3</i>	Forward	TGACAACAAACCGGTTACCA
	Reverse	TGTTTCTATTTCTCTCCCTACGC
<i>MMP2</i>	Forward	CCCACTGCGGTTTTCTCGAAT
	Reverse	CAAAGGGGTATCCATCGCCAT
<i>MMP9</i>	Forward	TCCACCCTTGTGCTCTTCCC
	Reverse	CTGCCACCCGAGTGTAACCAT
<i>IGF1R</i>	Forward	AGTGCTGTATGCCTCTGTGAACC
	Reverse	ATAGACCATCCCAAACGACCC
<i>18S rRNA</i>	Forward	ACCCGTTGAACCCCATTCGTGA
	Reverse	GCCTCACTAAACCATCCAATCGG
<i>HPRT</i>	Forward	CCTGGCGTCGTGATTAGTGAT
	Reverse	AGACG TTCAGTCCTGTCCATAA
<i>TNS3</i>	Forward	CAGGGGTGGTAAAGGACGC
	Reverse	GGAGGGCTCCATTAAAGCTGAA
<i>SOX18</i>	Forward	AAAGCGTGGAAGGAGCTGAA
	Reverse	CGGTA CTTGTAGTTGGGGTGGT
<i>NFATC3</i>	Forward	TATTTCGCACATCTTCATTACC
	Reverse	CCCTCGGCTACCTTCAGT
<i>GAPDH</i>	Forward	GCCAAGGTCATCCATGACA ACTTTGG
	Reverse	GCCTGCTTCACCACCTTCTTGATGTC
<i>Actb</i>	Forward	CATGTACGTTGCTATCCAGGC
	Reverse	CTCCTTAATGTCACGCACGAT

**Supplementary Table S7 PCR primers used for human genes cloning**

Human Genes		Primer sequences (5' to 3')
<i>YTHDF3</i>	Forward	CCGCTCGAGATGTCAGCCACTAGCGTGGA
	Reverse	GGGAAGCTTTTATTGTTTGTTTCTATTTCTCTCC
<i>YTHDF2</i>	Forward	CCGCTCGAGATGTCGGCCAGCAGCCTCTT
	Reverse	GCCGGTACCTTATTTCCCACGACCTTGACGT
<i>YTHDF1</i>	Forward	CCGCTCGAGATGTCGGCCACCAGCGTGGA
	Reverse	GCCGGTACCTCATTGTTTGTTTCGACTCTGCC
<i>IGF1R</i>	Forward	CCGGAATTCATGAAGTCTGGCTCCGGAGGAGG
	Reverse	CGCGGATCCTCAGCAGGTCGAAGACTGGGGC
<i>ALKBH3</i>	Forward	ATAAGAATGCGGCCGCCAATGGAGGAAAAAAGAC GGCGAG
	Reverse	CACGGGAAGCTTTCACCAGGGTGCCCCTCGAG